Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy [Yahoo! Finance]
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question [Yahoo! Finance]
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion [Yahoo! Finance]
Gilead Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]